Clal Biotechnology reported ILS-5.44M in EBIT for its fiscal quarter ending in December of 2022.





Ebit Change Date
Arca Biopharma USD -34.43M 326K Dec/2025
aTyr Pharma USD -121.47K 24.59M Mar/2026
Bio Path USD -488K 4.07M Sep/2025
Brainstorm Cell Therapeutics USD -2.05M 526K Sep/2025
Cara Therapeutics USD -5.94M 3.55M Sep/2025
Clal Biotechnology ILS -5.44M 3.76M Dec/2022
Compugen USD -9.02M 65.06M Mar/2026
Immunic USD -23.33M 2.67M Dec/2025
Minerva Neurosciences USD -4.37M 1.71M Sep/2024
RedHill Biopharma USD 2.69M 47.97M Jun/2023
TherapeuticsMD USD -1.77M 699K Sep/2023